Tenofovir (GS 1278) is an adenine analog REVERSE TRANSC-RIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.

Tenofovir alafenamide (GS-7340) is a nucleotide reverse transcriptase inhibitor (NRTI) and a novel ester prodrug of the antiretroviral tenofovir.

Tenofovir Disoproxil Fumarate (GS-1278 Disoproxil Fumarate) is a pro-drug, fumaric acid salt form of tenofovir, a nucleoside reverse transcriptase inhibitor analog of adenosine. Tenofovir disoproxil fumarate is prescribed to treat HIV and chronic hepatitis B virus (HBV) in adults.

(R,1R)-Tenofovir amibufenamide ((R,1R)-HS-10234) can be used as a Tenofovir prodrug, which can be taken orally and has antiviral activity. Tynofovir is a nucleotide reverse transcriptase inhibitor.

Tenofovir amibufenamide (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies.

Tenofovir Disoproxil (GS 4331) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

(S)-Tenofovir ((S)-PMPA) is the less active S-enantiomer of Tenofovir which is a nucleotide reverse transcriptase inhibitor.

Tenofovir alafenamide fumarate (GS-7340 fumarate) is an orally available Tenofovir precursor compound Tenofovir alafenamide fumarate has anti-HIV activity and can be used to prevent HIV infection.

Tenofovir exalidex (CMX 157) is a lipid-conjugated acyclic nucleotide analog of Tenofovir, demonstrating efficacy against wild-type and antiretroviral-resistant HIV strains, including those resistant to multiple nucleoside/nucleotide analogs. It effectively inhibits all major HIV-1 and HIV-2 subtypes in fresh human PBMCs, as well as all evaluated HIV-1 strains in monocyte-derived macrophages, displaying EC50 values between 0.2 and 7.2 nM. Oral administration of CMX157 shows no apparent toxicity. Additionally, Tenofovir exalidex exhibits antiviral properties against HBV.

Tenofovir disoproxil aspartate, a nucleotide reverse transcriptase inhibitor, is used potentially for the treatment of HBV infection.

Tenofovir-C3-O-C12-trimethylsilylacetylene (ammonium) displays a prolonged half-life (t1/2) compared to tenofovir in human liver microsomes. Moreover, it demonstrates potent in vitro anti-HIV activity and improves in vivo pharmacokinetic properties.

Tenofovir diphosphate is an inhibitor of HIV reverse transcriptase (Kis = 0.022 and 1.55 μM for RNA and DNA, respectively) and hepatitis B virus (HBV) polymerase (Ki = 0.18 μM). It is selective for these enzymes over DNA polymerase α and β, as well as mitochondrial DNA polymerase γ (Kis = 5.2, 81.7, and 59.5 μM, respectively). Tenofovir diphosphate is formed intracellularly through phosphorylation of the prodrugs tenofovir and tenofovir disoproxil by nucleotide kinases. Increased levels of tenofovir diphosphate in isolated peripheral blood mononuclear cells (PBMCs) correlate with a decrease in the risk of simian HIV (SHIV) acquisition in a macaque model of rectal SHIV transmission.

Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor used in the treatment of HIV and chronic Hepatitis B.

Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an oral phosphonoamidate prodrug of the HIV reverse transcriptase nucleotide inhibitor tenofovir (TFV)

Tenofovir diphosphate (TFV-DP) is a competitive inhibitor of DNA polymerases, specifically targeting dATP, and it serves as a substrate for the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1)[1].

Tenofovir diphosphate triethylamine (TFV-DP triethylamine) is a competitive inhibitor of DNA polymerases for dATP, functioning as a substrate for HIV type 1 reverse transcriptase (HIV-1 RT)[1].

Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor used in the treatment of HIV and chronic Hepatitis B.

Tenofovir-C3-O-C15-CF3 (ammonium) demonstrates prolonged half-life values compared to tenofovir in human liver microsomes. It exhibits potent anti-HIV activity in vitro and enhances pharmacokinetic properties in vivo.

(Z)-9-Propenyladenine is a mutagenic impurity in tenofovir disoproxil fumarate.

9-Propenyladenine is a mutagenic impurity in tenofovir disoproxil fumarate.

Antiviral agent 9 exhibits potent efficacy against HIV-1 with an EC50 value of 0.006 nM, indicating extremely low concentrations are sufficient to inhibit the virus. Additionally, it demonstrates a selectivity index (SI) nearly 300 times higher than that of tenofovir alafenamide fumarate (TAF), outlining its superior selectivity and potential safety profile.

trans-Urocanic Acid ((E)-Urocanic acid), a compound predominantly distributed in the hippocampus and prefrontal cortex, is an isomer of cis-UCA, an epidermal UV-protectant, which enhances the stability of tenofovir eplerenomide in long-acting HIV applications. trans-Urocanic acid potently modulates immune trans-urocanic acid effectively modulates immune function, inhibits human natural killer cell activity in vitro, and can be used in Alzheimer's disease research.

cis-Urocanic acid ((E)-Urocanic acid) is a 5-HT2A receptor agonist (Kd: 4.6 nM). It is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.

Urocanic acid (4-Imidazoleacrylic acid), synthesized in the epidermis, functions as a primary absorber of ultraviolet (UV) radiation in mammalian skin.